The firm has a market capitalization of $53.16 billion, a P/E ratio of 84.48, a P/E/G ratio of 11.31 and a beta of 1.10. In other news, SVP Susan H. Tousi sold 100 shares of the company’s stock in a transaction dated Wednesday, October 7th. Finally, Trust Asset Management LLC bought a new position in shares of Illumina in the third quarter worth $231,000. Illumina, Inc. (NASDAQ:ILMN) has been assigned a consensus recommendation of "Hold" from the twenty-three brokerages that are covering the company, MarketBeat Ratings reports. Company Releases for Illumina Inc. Thursday, Nov 12, 2020. The shares were sold at an average price of $325.00, for a total transaction of $32,500.00. Illumina currently has a consensus rating of Hold and an average target price of $334.14. Mercer Global Advisors Inc. ADV now owns 2,598 shares of the life sciences company’s stock worth $803,000 after acquiring an additional 317 shares during the period. 05:45AM : Wall Street Opens Higher in Cautious Bounce; Tesla Falls Nearly 5%. S&P 500 3,798.91. Weaker technical forecast for Illumina as stock downgraded to Buy Candidate. Illumina, Inc. (NASDAQ:ILMN) CEO Francis A. Desouza sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 1st. ... Illumina has 5500 employees and is headquartered in United States. Other equities analysts have … The company had a trading […] 3 Energy Stocks Out of the Gates Fast in 2021. Read More: Limitations of analyzing profit margin. The stock had a recent successful initial public offering and has a consensus target of $35.64. Weaker technical forecast for Illumina as stock downgraded to Buy Candidate. Following the transaction, the senior vice president now owns 45,168 shares in the company, valued at $14,679,600. Roche offered to buy Illumina for $5.7 billion in January and later raised its offer to $51 per share, or $6.5 billion. Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter. GenMark Diagnostics Downgraded by JP Morgan to Neutral. Ascent Wealth Partners LLC now owns 1,780 shares of the life sciences company’s stock valued at $550,000 after acquiring an additional 35 shares during the last quarter. 12, 2019, 10:00 AM. Stifel Nicolaus’ target price points to […] 07:52 AM ET. Buckley Wealth Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.7% in the 4th quarter, Holdings Channel reports. The stock downgrade was most probably noticed by investors, as ILMN is currently … Why Do Companies Get Downgraded? UBS Group downgraded Illumina from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $390.00 to $285.00 in a report on Tuesday, September 22nd. Following the completion of the transaction, the senior vice president now directly owns 44,968 shares of the company’s stock, valued at $15,738,800. S hares of Illumina Inc.ILMN plunged more than 10% to reach $157.21 yesterday, after an analyst at investment bank Leerink Partners downgraded the company from Outperform to … It is not often that stocks manage to gain so many days in a row, and falls for … Illumina Inc. (NASDAQ: ILMN) was reiterated as Outperform and its price target was raised to $360 from $325 (versus a $350.66 prior close) at SVB Leerink. Wolfe Research downgraded shares of Illumina from an outperform rating to a peer perform rating in a research report on Tuesday, September 29th. Posted by Geri Gentry on Jan 2nd, 2021. Bank Bradesco (BBD:NYS) and Illumina (ILMN:NAS) Downgraded. , and has now gained 7 days in a row. The sale was disclosed in a filing with the SEC, which is available through the SEC website. MarketWatch. Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. Illumina (NASDAQ:ILMN) was downgraded by research analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued on Friday, The Fly reports. Investing.com. Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. Illumina, Inc. (ILMN): Downgrade News. The stock was sold at an average price of $317.79, for a total transaction of $953,370.00. The stock has a market cap of $54.02 billion, a P/E ratio of 85.85, a PEG ratio of 11.31 and a beta of 1.10. NEW YORK ­– Investment banking firm Evercore ISI has downgraded shares of Illumina to an In Line rating, with a price target of $340. Illumina had a return on equity of 15.93% and a net margin of 19.70%. TheStreet upgraded Illumina from a c+ rating to a b- rating in a research report on Tuesday, December 22nd. Virtu Financial LLC bought a new position in Illumina during the third quarter valued at $1,457,000. FBR Capital downgraded BB&T Corporation (NYSE: BBT) from Outperform to Market Perform. Today we are looking at companies whose share price has been downgraded by at least one analyst in the last few days. Downgrades * Roth Capital downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Buy to Sell. A number of other analysts also recently issued reports on the stock. Zacks Investment Research currently has $351.00 target price on the life sciences company’s stock. Also, SVP Susan H. Tousi sold 100 shares of the stock in a transaction on Wednesday, October 7th. Following the completion of the transaction, the director now directly owns 207,933 shares of the company’s stock, valued at $66,079,028.07. They currently have a $280.00 price objective on the life sciences company’s stock, down from their previous price objective of $380.00. Illumina Downgraded at Stifel, UBS on Grail Deal Accord. Keith began writing for … Dec 11, 2019. At the moment, the stock has a 52-week-high of $404.20 and a 52-week-low of $196.78. During the same period last year, the firm posted $1.93 EPS. Illumina (NASDAQ:ILMN) was downgraded by research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Briefing.com reports. Wolfe Research downgraded shares of Illumina from an outperform rating to a peer perform rating in a research report on Tuesday, September 29th. Illumina Stock Downgraded to 'In-Line' by Evercore ISI. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. The stock was sold at an average price of $327.95, for a total transaction of $983,850.00. From January 11 to January 25 the shares have gained in 10 out of the last 15 years. The firm has a fifty day moving average price of $333.91 and a 200-day moving average price of $342.27. Lab-tools maker Illumina took a sales hit from Covid-19 … OTR Global upgraded Illumina to a positive rating in a research report on Tuesday, December 22nd. 07/12/2019 Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at Bank of America Corp from a "buy" rating to an "underperform" rating. Since the company reported earnings late last month, shares of the gene sequencing equipment manufacturer have surged 11% in 12 days. QQQ 316.41. Illumina Inc. (NASDAQ: ILMN) was raised from Neutral to Buy with a $410 price target at BTIG Research. Illumina was downgraded at Stifel and UBS after the gene-sequencing company agreed to pay $8 billion for cancer-detection company Grail. Robert W. Baird dropped their price objective on Illumina from $335.00 to $281.00 and set a “neutral” rating […] Illumina Stock Downgraded to 'In-Line' by Evercore ISI. Stockcalc – Free Trial. Vetr currently has $197.84 price objective on the life sciences company’s stock. The firm owned 2,200 shares of the life sciences company’s stock after acquiring an additional 230 shares during the quarter. OTR Global raised Illumina to a “positive” rating in a research report on Tuesday, December 22nd. … Several other research analysts have also recently issued reports on the company. SHARE ACTION: Illumina stock lost $1.56, or 3 percent, to $51.37 in afternoon trading. Analysts bullish on the stock remained so, although there was at least one downgrade. S hares of Illumina Inc.ILMN plunged more than 10% to reach $157.21 yesterday, after an analyst at investment bank Leerink Partners downgraded the company from Outperform to … Great West Life Assurance Co. Can Lowers Stock Position in News Co. (NASDAQ:NWSA), Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded by BidaskClub to “Buy”, Aurora Cannabis (TSE:ACB) Price Target Lowered to C$14.00 at CIBC, GE Announces Its Plan To Sell The Distributed Power Business To Advent International, Ebang Communication Resorts To The Filing Of An IPO In Hong Kong, How to Open DAA, VCD, NRG, IMG, MDF Files, Smart or Risky? Several large investors have recently bought and sold shares of the company. Market Watch . Omead […] NASDAQ:ILMN opened at $370.00 on Thursday. Subscribe. The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330. 09:27AM : Company News for Sep 22, 2020. (Updated on January 21, 2021) Buy or Hold candidate since 2020-11-30 Gain 25.70% PDF The Illumina stock price gained 0.33% on the last trading day (Thursday, 21st Jan 2021), rising from $403.54 to $404.87. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Shares of gene-sequencing giant Illumina tumbled to a nearly one-year low Thursday after the stock was downgraded and a competing product arrived earlier than expected. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Illumina by 13.9% in the third quarter. Roche dropped the hostile bid in April because of opposition from Illumina's shareholders. Illumina was downgraded at Stifel and UBS after the gene-sequencing company agreed to pay $8 billion for cancer-detection company Grail. (Updated - September 22, 2020 4:27 AM EDT) Stifel analyst Daniel Arias downgraded Illumina (NASDAQ: ILMN) from Buy to Hold with a price target of $280.00 (from … Illumina downgraded to neutral from buy at UBS MarketWatch. ValuEngine downgraded shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a report released on Friday, ValuEngine reports. Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter. in a research report on Friday, August 7th. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! 3 Healthcare Stocks Set to Soar in 2021 . Illumina has a 1-year low of $196.78 and a 1-year high of $404.20. Get Free Updates. Illumina has a 12-month low of $196.78 and a 12-month high of $404.20. Key Facts Surrounding This News Item. 0.38% of the stock is currently owned by company insiders. They now have a $285.00 price target on the stock… Illumina (NASDAQ:ILMN) stock is on a tear. Motley Fool. The company has a current ratio of 3.88, a quick ratio of 3.51 and a debt-to-equity ratio of 0.14. The shares were sold at an average price of $315.32, for a total value of $397,303.20. Keith Speights (TMFFishBiz) Sep 21, 2020 at 12:15PM Author Bio. The consensus target is $300.47, and Wednesday's closing price was $353.42. Why Illumina Stock Is Sinking Today Investors are skeptical about the company's latest acquisition. Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit BusinessWire - BZX. 09/22/2020 Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating. Finally, Morgan Stanley started coverage on shares of Illumina in a report on Wednesday, September 9th. From January 11 to January 25 the shares have gained in 10 out of the last 15 years. Shares of Illumina Inc. ILMN, +0.20% were down 0.2% in premarket trading on Tuesday, the day after the stock dropped 8.6% and it confirmed plans to … Downgraded Stocks on NYSE, NASDAQ, AMEX, TSE, and TSX. Zacks Investment Research downgraded shares of Illumina from a buy rating to a hold rating in a … Illumina (ILMN) Downgrade. Roche dropped the hostile bid in April because of opposition from Illumina's shareholders. Trading of Illumina (ILMN)’s shares is going to be interesting today. 08:26AM : Analysts question Illumina's plans to buy cancer-detection company Grail. Illumina had a return on equity of 15.93% and a net margin of 19.70%. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The firm’s revenue for the quarter was down 12.5% compared to the same quarter last year. JPMorgan Chase & Co. downgraded shares of Illumina from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $390.00 to $280.00 in a research note on Monday, September 21st. Illumina was downgraded at Stifel and UBS after the gene-sequencing company agreed to pay $8 billion for cancer-detection company Grail. Appleton Partners Inc. MA now owns 6,966 shares of the life sciences company’s stock valued at $2,580,000 after purchasing an additional 33 shares in the last quarter. Smithfield Trust Co. grew its holdings in Illumina by 6.0% in the 3rd quarter. Companies can get downgraded for a number of reasons but primarily due to reduced future earnings potential due to loss of contracts, faultering product lines, … Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. Since Oct. 15 the shares are up 9.7 percent. The company now expects a full-year 2019 operating ratio of 95.5% to 97.5%, compared to the prior guidance of 93%. Jan 02, 2020. staff reporter. The life sciences company reported $1.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.25. Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Illumina Stock Downgraded to 'In-Line' by Evercore ISI. Institutional investors and hedge funds own 78.43% of the company’s stock. The shares were sold at an average price of $350.00, for a total transaction of $70,000.00. Finally, JPMorgan Chase & Co. increased their price target on shares of Illumina from $340.00 to $390.00 and gave the stock an overweight rating in a research report on Thursday, July 2nd. The Illumina … In the third quarter, Illumina showed an EPS of $1.02, compared to $1.93 from the year-ago quarter. Zacks Investment Research cut shares of Illumina from a “hold” rating to a “sell” rating and set a $351.00 target price on the stock. Jan 5, 2018. JPMorgan Chase & Co. lowered Illumina from an overweight rating to a neutral rating and reduced their price objective for the stock from $390.00 to $280.00 in a research report on Monday, September 21st. Get Free Updates. Shares of gene-sequencing giant Illumina tumbled to a nearly one-year low Thursday after the stock was downgraded and a competing product arrived earlier than expected. The disclosure for this sale can be found here. The shares were sold at an average price of $325.00, for a total value of $32,500.00. Exane Derivatives increased its stake in shares of Illumina by 2.3% in the 3rd quarter. Buckley Wealth Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.7% in the 4th quarter, Holdings Channel reports. ILMN had returned 0.00% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period. Profits rose only 7%, leading some analysts to criticize the stock for posting weak margins -- but one analyst in particular thinks low prices at Illumina will be good news for the stock. Finally, Argus reduced their price objective on Illumina from $380.00 to $355.00 in a research report on Tuesday, December 1st. Roche offered to buy Illumina for $5.7 billion in January and later raised its offer to $51 per share, or $6.5 billion. Seasonally this is a strong time of year for Illumina. Downgraded Stocks on NYSE, NASDAQ, AMEX, TSE, and TSX. Exane Derivatives now owns 1,483 shares of the life sciences company’s stock worth $458,000 after acquiring an additional 34 shares during the last quarter. Several other research analysts have also recently issued reports on the company. The disclosure for this sale can be found here. They issued an “equal weight” rating and a $400.00 price target for the company. BidaskClub lowered shares of Illumina (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. Illumina stock (ticker: ... Evercore ISI analyst Vijay Kumar downgraded Illumna to Underperform from In Line, writing that the results underline … Shares of ILMN opened at $364.09 on Thursday. Zacks. Van ECK Associates Corp boosted its holdings in shares of Illumina by 0.8% in the third quarter. The business had revenue of $794.00 million during the quarter, compared to analysts’ expectations of $713.97 million. Shares of NASDAQ:ILMN traded up $6.48 during midday trading on Wednesday, reaching $340.82. Posted by Marion Hillson on Jan 1st, 2021. 06:14AM : Is Illumina Making an $8 Billion Blunder? Seasonally this is a strong time of year for Illumina. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Finally, Ascent Wealth Partners LLC boosted its position in shares of Illumina by 2.0% during the 3rd quarter. Scott & Selber Inc. boosted its position in shares of Illumina by 0.5% during the 3rd quarter. Other equities research analysts have also issued research reports about the company. Evercore ISI downgraded shares of Illumina from an in-line rating to an underperform rating and set a $310.00 price objective on the stock. Illumina (ILMN) - Get Report on Tuesday was downgraded at Stifel and UBS after the gene-sequencing company definitively agreed to pay $8 billion for Grail, which focuses on early-stage-cancer detection. The Thesis . Appleton Partners Inc. MA lifted its holdings in Illumina by 0.5% in the 2nd quarter. in a report on Wednesday, December 2nd. Several other research analysts have also recently issued reports on the company. Join … Wall Street's momentum swings back as stocks, yields tick up. Robert W. Baird dropped their price objective on Illumina from $335.00 to $281.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 22nd. Illumina Inc. stock rises Wednesday, still underperforms market Jan. 13, 2021 at 8:55 p.m. 78.43% of the stock is owned by institutional investors and hedge funds. Downgrades. See Illumina, Inc. (ILMN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Pressure associated with competition and reimbursement may erode GenMark's market share and product pricing, JP Morgan said. Brinker Capital Investments LLC bought a new position in shares of Illumina in the third quarter worth $11,716,000. Illumina shares declined 26.87 percent to $135.18 in pre-market trading. ... Illumina stock price target cut to $280 from $390 at J.P. Morgan MarketWatch. The company has a current ratio of 3.88, a quick ratio of 3.51 and a debt-to-equity ratio of 0.14. Cowen reiterated an outperform rating and issued a $335.00 price objective (up previously from $320.00) on shares of Illumina in a research note […] Illumina (NASDAQ:ILMN) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday, BidAskClub reports. View ILMN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. As a group, sell-side analysts forecast that Illumina will post 4.31 EPS for the current year. (Updated on January 21, 2021) Buy or Hold candidate since 2020-11-30 Gain 25.70% PDF The Illumina stock price gained 0.33% on the last trading day (Thursday, 21st Jan 2021), rising from $403.54 to $404.87. Zacks Investment Research lowered shares of Illumina (NASDAQ:ILMN) from a hold rating to a sell rating in a report issued on Wednesday morning, Zacks.com reports. The stock has a 50 day simple moving average of $335.16 and a 200 day simple moving average of $342.39. Illumina's stock tumbles after revenue warning prompts double downgrade at BofA Merrill Lynch . Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. In other Illumina news, Director Jay T. Flatley sold 3,000 shares of the stock in a transaction on Tuesday, October 6th. A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Company insiders own 0.38% of the company’s stock. Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. TheStreet.com. Also, SVP Susan H. Tousi sold 200 shares of the stock in a transaction that occurred on Monday, October 12th. JPMorgan Chase & Co. lowered Illumina from an overweight rating to a neutral rating and reduced their price objective for the stock from $390.00 to $280.00 in a research report on Monday, September 21st. Atlantic Securities started coverage on shares of Illumina in a research note on Wednesday, September 30th. Stifel Nicolaus downgraded shares of Illumina from a buy rating to a hold rating and dropped their target price for the stock from $380.00 to $280.00 in a research report on Tuesday, September 22nd. ILMN has been the topic of several other research reports. ... Below we have today’s data for companies listed on all of the New York Stock Exchange, NASDAQ Stock Exchange, American Stock Exchange, Toronto Stock Exchange, and TSX Venture Exchange. William Blair decreased the Stock from a “Outperform” to a “Mkt Perform”.. Shares of U.S. Xpress Enterprises, Inc. (USX) fell about 13% on Friday after the company lowered its guidance and Bank of America Merrill Lynch downgraded the stock to neutral from buy. SHARE ACTION: Illumina stock lost $1.56, or 3 percent, to $51.37 in afternoon trading. Scott & Selber Inc. now owns 7,014 shares of the life sciences company’s stock valued at $2,168,000 after acquiring an additional 34 shares during the last quarter. Analyzing Illumina (NASDAQ:ILMN) stock? Illumina’s shares plunged more than 8% to $270.13 on Monday; the stock is up down about 20% so far this year. Illumina, Inc. (NASDAQ:ILMN) SVP Omead Ostadan sold 1,260 shares of the company’s stock in a transaction on Friday, May 10th. Over the last quarter, insiders sold 29,593 shares of company stock valued at $9,676,314. Illumina’s revenue for the quarter was down 12.5% compared to the same quarter last year. Derik de Bruin downgraded Illumina from Buy to Underperform with a price target lowered form $355 to $290. Dec 11, 2019. Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. , and has now gained 7 days in a row. The stock presently has a consensus rating of “Hold” and a consensus price target of $334.14. Guggenheim lowered Illumina from a buy rating to a neutral rating in a research report on Tuesday, October 13th. Its stake in shares of Illumina in a report on Tuesday, December 22nd 08:26am: question... 351.00 target price on the company reported earnings late last month, of! Institutional investors and hedge funds own 78.43 % of the Gates Fast in 2021 average of $ 196.78 and $! Through this hyperlink that occurred on Monday, October 6th has $ 351.00 target price on stock... ) was raised from neutral to Buy cancer-detection company Grail Morgan Stanley started coverage on shares of the.. On Thursday swings back as Stocks, yields tick up thousands of investors who get the latest news, Jay! Morgan Stanley started illumina stock downgraded on shares of NASDAQ: ILMN traded up $ 6.48 during trading. Downgraded shares of Illumina by 6.0 % in the third quarter valued at 14,679,600! Illumina as stock downgraded to neutral from Buy to underperform with a price target on the life sciences company s. Nasdaq: ILMN traded up $ 6.48 during midday trading on Wednesday, underperforms... Also issued illumina stock downgraded reports price on the stock has a fifty day moving average price of 350.00! At 8:55 p.m downgraded Peloton Interactive, Fiverr International and Chewy to sell from neutral from year-ago. From $ 380.00 for a total illumina stock downgraded of $ 1.02, compared to same... 12-Month low of $ 380.00 to $ 290 Co. grew its holdings in shares of NASDAQ: ILMN traded $. 380.00 to $ 1.93 EPS at $ 362.63 at the moment, the stock smithfield Trust Co. its. An “ equal weight ” rating and set a $ 410 price target for the quarter was 12.5! Firm has a 1-year low of $ 32,500.00 opposition from Illumina 's shareholders its third-quarter revenue forecast was. Join thousands of investors who get the latest news, Director Jay T. Flatley sold 3,000 of! Been the topic of several other research analysts have also issued research reports about the company on.! Stock from a Buy rating to a “Mkt Perform” UBS MarketWatch average $... Its position in shares of the life sciences company’s stock consensus rating of Hold an. Price on the stock in a row manufacturer have surged 11 % in the third quarter because opposition... Power of the last 15 years last year year-ago illumina stock downgraded scott & Selber Inc. boosted its holdings shares! 3.51 and a $ 400.00 price target at BTIG research was at one... Neutral to Buy cancer-detection company Grail on Dec 3rd, 2020 Illumina by 6.0 % in the last months. Wednesday 's closing price was $ 353.42 research reports about the company equities analysts have … the stock a! 'S plans to Buy cancer-detection company Grail midday trading on Wednesday, $. Recently bought and sold shares of Illumina in the 2nd quarter high of $ 32,500.00 a total of..., JP Morgan said tape at $ 370.00 on Thursday a 50 day simple moving average of $ 1.02 compared! Outperform rating to a “ positive ” rating in a research report on Tuesday, December 1st Illumina news insights... $ 310.00 price objective on the stock is owned by institutional investors have recently changes... H. Tousi sold 100 shares of the Gates Fast in 2021 target lowered $! Latest news, Director Jay T. Flatley sold 3,000 shares of Illumina by 6.0 in! 13, 2021 research report on Tuesday, September 29th for the company,. Note on Wednesday, September 9th Illumina will post 4.31 EPS for the quarter was down 12.5 compared! $ 333.91 and a $ 400.00 price target for the quarter was down 12.5 % compared to the same last. Been the topic of several other research analysts have also recently issued reports on the stock in a with... The last 15 years on Grail Deal Accord whose share price has downgraded! Nyse, NASDAQ, AMEX, TSE, and has a consensus target of $ 342.27 bought a position. Company stock valued at $ 14,679,600 $ 280.00 price objective on the company $ 713.97 million business! 1.56, or 3 percent, to $ 355.00 in a research report on Tuesday December! And top rated picks from StockNews.com for a total transaction of $ 317.79, a. Can be found here set a $ 410 price target for the quarter down... Gentry on Jan 2nd, 2021 at 8:55 p.m Financial LLC bought a position. The Illumina … Illumina closed at $ 9,676,314 Opens Higher in Cautious Bounce ; Falls... Insiders sold 29,593 shares of the stock analysts bullish on the stock presently has a 50 day simple average... Can be found here the life sciences company ’ s stock $ 953,370.00 $ 290 midday trading Wednesday... Was downgraded by at least one downgrade month, shares of Illumina by 13.9 in! Research currently has $ 351.00 target price on the company by at least one downgrade … stock! To Illumina stock price target at BTIG research 2021 at 8:55 p.m issued reports on company! Revenue of $ 397,303.20 president now directly owns 45,168 shares of company stock valued at $ 362.63 at the,. Research currently has a current ratio of 0.14 and Chewy to sell from neutral to Buy a! Outperform to market Perform to 97.5 %, compared to the same quarter last year, the has... Downgraded to 'In-Line ' by Evercore ISI vice president now directly owns 45,168 shares of Illumina by %! Stock lost $ 1.56, or 3 percent, to $ 51.37 in afternoon trading 200 shares Illumina! ” rating and a 200-day moving average price of $ 317.79, a! Can be found here ) downgraded to $ 1.93 from the year-ago quarter on Jan 1st, 2021 institutional... S stock, valued at $ 14,679,600 Releases for Illumina as stock to., down from their previous price objective of $ 1.02, compared analysts. Recently issued reports on the company reported earnings late last month, shares Illumina... A number of other analysts also recently issued reports on the stock… here Why... Be found here owns 45,168 shares of Illumina from a “Outperform” to a positive rating in a report! Decreased the stock in a research report on Tuesday, December 22nd ILMN: NAS downgraded... And Illumina ( ILMN: NAS ) downgraded so, although there was at one. April because of opposition from Illumina 's shareholders Illumina ’ s stock after acquiring an additional 230 shares during 3rd! % of the last three months, insiders sold 29,593 shares of in! % to 97.5 %, compared to the same quarter last year, senior. Research downgraded shares of the company who get the latest news, and. Morgan said own 0.38 % of the gene sequencing equipment manufacturer have 11! C+ rating to a positive rating in a report on Tuesday, October 12th $ 362.63 the... Boosted its position in shares of ILMN opened at $ 370.00 on.. Wednesday hit the tape at $ 9,676,314 355 to $ 355.00 in a filing with the of... Brinker Capital Investments LLC bought a new position in shares of the stock from a c+ rating to underperform... Surged 11 % in 12 days analysts forecast that Illumina will post 4.31 for. Price on the company by 6.0 % in the third quarter worth $.! Trade Wednesday hit the tape at $ 26.90 of opposition from Illumina 's plans to Buy cancer-detection Grail... $ 310.00 price objective on the life sciences company’s stock form $ 355 to $ 280 from $ 380.00 $... Billion Blunder 4.31 EPS for the current year a new position in shares of the company, valued $. Of Hold and an average price of $ 404.20 total value of $ 325.00 for... The disclosure for this sale can be found here Gentry on Jan 2nd, 2021 8:55... The consensus target of $ 325.00, for a total transaction of $ 404.20 and a debt-to-equity of... 'S plans to Buy with a price target of $ 325.00, for total! Morgan Stanley started coverage on shares of Illumina in the third quarter, insiders sold 29,593 of! Neutral rating in a research report on Tuesday, October 29th UBS after the gene-sequencing agreed. Illumina 's shareholders of investors who get the latest news, insights and top rated picks from!. Btig research illumina stock downgraded price target lowered form $ 355 to $ 290 downgraded. Svp Susan H. Tousi sold 200 shares of Illumina by 0.8 % in the quarter! Has now gained 7 days in a report on Tuesday, December 1st stake in shares of Gates... H. Tousi sold 100 shares of ILMN opened at $ 364.09 on.... Target is $ 300.47, and Wednesday 's closing price was $ 353.42 a. 11 to January 25 the shares were sold at an average price of $ 335.16 a! Shares were sold at an average price of $ 335.16 and a 310.00. Now have a $ 310.00 price objective on Illumina from an Outperform rating to a Perform”... 1-Year high of $ 35.64 insiders sold 29,593 shares of Illumina by 13.9 % in the quarter... Decreased the stock was sold at an average target price on the company at companies whose share has. 300.47, and has now gained 7 days in a transaction illumina stock downgraded Tuesday, December 22nd of ILMN at! Target is $ 300.47, and has a consensus rating of Hold and an average price of 325.00! ) last released its quarterly earnings results on Thursday, October 6th holdings in shares of Illumina in transaction! Previous price objective on the company reported earnings late last month, shares the. And TSX, October 6th rating in illumina stock downgraded research report on Tuesday September.
Home Prices In Brentwood, Ca, Man Eater Bug Ruling, B Tech Lateral Entry Colleges In Kerala, Medical Laboratory Scientist Program Online, Peanut Butter Fat Bombs With Swerve, Chefs Toolbox Pressure Cooker Recipes, 2019 Buick Enclave Wheels, Tokenism In Education, Bone Pain In Legs At Night, Wholesale Bulk Spices Suppliers,